Biomédecine translationnelle

  • ISSN: 2172-0479
  • Indice h du journal: 16
  • Note de citation du journal: 5.91
  • Facteur d’impact du journal: 3.66
Indexé dans
  • Ouvrir la porte J
  • Genamics JournalSeek
  • JournalTOCs
  • RechercheBible
  • Le facteur d'impact global (GIF)
  • Infrastructure nationale des connaissances en Chine (CNKI)
  • CiteFactor
  • Scimago
  • Bibliothèque des revues électroniques
  • Répertoire d'indexation des revues de recherche (DRJI)
  • OCLC - WorldCat
  • Invocation de Proquête
  • Publions
  • MIAR
  • Commission des bourses universitaires
  • Fondation genevoise pour la formation et la recherche médicales
  • Google Scholar
  • SHERPA ROMÉO
  • Laboratoires secrets des moteurs de recherche
  • ResearchGate
Partager cette page

Abstrait

Impacts of Translational Biomedicine

William Robert

The family of interferon (IFN) proteins has now quite reached the potential envisioned by early discovering virologists: IFNs aren't only antivirals with a spectrum of clinical effectiveness against both RNA and DNA viruses, but also are the prototypic biological response modifiers for oncology, and show effectiveness in suppressing manifestations of MS. The invention and molecular understanding of the cellular mechanisms and clinical use of interferon (IFNs) has been a serious advance in biomedicine over the past 50 years. This family of secreted anticrime and paracrine proteins stimulates intracellular and intercellular networks that regulate resistance to viral infections, enhance innate and purchased immune responses, and modulate normal and tumor cell survival and death.